Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A New Intervention for Implementation of Pharmacogenetics in Psychiatry
2023-509680-25-00Phase 4Authorised
- Sponsor
- Parnassia Groep
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 4 trial of escitalopram, sertraline, risperidone and aripiprazole in major depressive disorder (MDD), bipolar disorder (BD), panic disorder and 6 more (3 arms), sponsored by Parnassia Groep. Primary endpoint: Patient recovery at 24 weeks. Planned start Nov 2024; status: authorised.
02
Drugs
escitalopramsertralinerisperidonearipiprazole
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)panic disorderSocial Anxiety Disorder (SAD)specific phobia
Beyond the preview
Go deeper on 2023-509680-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509680-25-00.